Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Combination of oxymetazoline and ipratropium in topical nasal application for the treatment of a cough

A technology of ipratropium bromide, oxymetazoline hydrochloride, applied in the field of combination of oxymetazoline and ipratropium bromide for topical nasal application for the treatment of cough, able to solve problems such as not being available from the market

Inactive Publication Date: 2018-08-31
帕博罗柯德思博瑞格
View PDF6 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] However, formulations for intranasal use comprising oxymetazoline salts or derivatives and ipratropium bromide salts or derivatives have not been described and are currently not available on the market, especially for the relief of nasal mucus that flows backwards into the nasopharynx. Preparations for increased coughing (otherwise known as postnasal drip syndrome)

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Combination of oxymetazoline and ipratropium in topical nasal application for the treatment of a cough
  • Combination of oxymetazoline and ipratropium in topical nasal application for the treatment of a cough
  • Combination of oxymetazoline and ipratropium in topical nasal application for the treatment of a cough

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0018] The purpose of designing the present invention is to use the combination of ipratropium bromide and oxymetazoline hydrochloride intranasally (or each component is used alone) to symptomatic treatment cough caused by postnasal drip syndrome.

[0019] The term "symptomatic treatment of cough" refers to medical and pharmacological interventions intended to reduce or eliminate cough, i.e., as antitussive agents, which do not necessarily act on the primary cause of cough (such as viral or bacterial infection, or immune disorder), but rather its consequences (often postnasal drip syndrome, which directly causes coughing).

[0020] It refers to coughs mainly caused during viral nasopharyngitis (so-called "flu", "cold" or "cold") and caused by bacterial infections (such as nasopharyngitis or bacterial rhinitis) that prolong the course of the cough. - Cough due to sinusitis).

[0021] Furthermore, the cough it refers to is a cough that tends to worsen mainly at night and in the...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention is effective for the treatment and relief of a cough caused by posterior nasal secretion, using the combination of oxymetazoline and ipratropium. The stated active agents in the combination according to the invention have been used and marketed separately with different uses to those according to the invention. The oxymetazoline is market for eliminating nasal secretion and congestion (blockage), and the ipratropium bromide is marketed for the purpose of dilating the bronchi in asthmatic patients and patients with chronic obstructive pulmonary disease, although it has also be used experimentally for reducing nasal secretion. Both active agents, together or separately, have not yet been used as intranasal antitussives. The cough caused by posterior nasal secretion is the mostcommon cause of a cough in humans of any age, and this invention is effective for the treatment and relief of said symptom.

Description

technical field [0001] The present invention relates to the use of oxymetazoline and ipratropium administered nasally in combination or each alone for the relief of cough. The cough is caused by a postnasal discharge. Background technique [0002] Ipratropium is a derivative of N-propylnortropine, which has anticholinergic effects in the upper respiratory tract. The basic patent is US 3505337. For the symptomatic treatment of rhinorrhea associated with perennial rhinitis, nasal sprays are commercially available [0003] Oxymetazoline is an imidazole-sympathetic vasoconstrictor preferably used topically intranasally to decongest the nasal mucosa. The basic patent of oxymetazoline is DE 1117588 ( Iliadin, metered dose aerosol, drops, pediatric aerosol, available on the market). An aerosol formulation containing ipratropium and xylomezoline (a similar molecule) (Otrivin ). Combinations of derivatives of oxymetazoline or its salts and derivatives of ipratropium or its...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/4174A61K31/46A61P11/14
CPCA61K31/4174A61K31/46A61P11/14A61K9/0043A61K2300/00A61K9/08A61K47/02A61K47/10A61K47/183A61K47/186
Inventor 帕博罗·柯德思·博瑞格
Owner 帕博罗柯德思博瑞格
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com